Acathia Capital Increases Stake in Swedish Savings Platform Futur
3.12.2024 17:46:00 CET | Business Wire | Press release
Acathia Capital has signed its second GP-led secondary transaction thereby increasing its stake in Futur, Sweden's leading pension and savings platform. For this investment Acathia Capital is backed by Montana Capital Partners, a global private equity secondaries investment manager and part of PGIM, the global investment management business of Prudential Financial, Inc. (NYSE: PRU). MCP serves as the main investor in this transaction, alongside a German insurance company.
Since 2019, Acathia Capital and Nordic private equity manager Polaris Private Equity have jointly lead-managed the investment in Futur alongside 3 passive co-investors. In this transaction, Acathia Capital acquired shares from one co-investor through its new vehicle Fjord Pension SCS.
The transaction is another milestone in the journey of Acathia Capital’s successful investment strategy of full conviction investments on a deal-by-deal basis in the financial services sector. Acathia now manages over EUR 300 million AuM.
Futur exemplifies the power of digitalization in the savings market. The company has redefined Sweden’s life insurance market through cost and service leadership, gaining significant market share through end-to-end digitalization and full scalability.
Thanks to its fully digitalized operations, Futur benefits from unique competitive advantages, including:
- Best-in-class partner satisfaction
- Unrivalled cost efficiency
- Leading product innovation capability
Dr. Thomas Schmitt, Managing Partner at Acathia Capital, remarked: “Since our investment in Futur began in 2019, Futur has tripled its assets under management to SEK 240bn. and more than quadrupled its profits, establishing itself as a market leader in Sweden.”
Torgny Johansson, CEO of Futur, says: “We stick to our strategy, to be independent and focus on simplicity for our partners as well as our joint customers.”
About Futur
Futur is a technology-powered pension and savings platform with a life insurance license. It offers long-term savings and insurance cover, with a particular focus on occupational pension and capital insurance. The platform offers leading efficiency, simplicity and access to an independent, quality proofed fund offering. Futur administers over SEK 240bn AuM in 2024 in the form of unit-linked insurance policies.
About Acathia Capital
Acathia Capital specializes in investments in fully regulated insurers and banks across Europe and manages over EUR 300 million in investments for German and Swiss institutional investors. With a track record of creating top-quartile returns for investors, Acathia Capital drives transformative growth in its portfolio companies.
The closing of the transaction is subject to approval of the Swedish Financial Supervisory Authority.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241203919861/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom